His scientific interests lie mostly in Molecular biology, Antigen, Antibody, In vivo and Mutant. His research in Molecular biology intersects with topics in HER2/neu, Pancreatic cancer, Monoclonal antibody and Epidermal growth factor receptor. His Antigen research integrates issues from Amino acid and Immunotoxin.
His studies in Antibody integrate themes in fields like Cancer cell, Nanoparticle and Internalization. His work on Biodistribution as part of general In vivo research is often related to Divalent, thus linking different fields of science. His studies deal with areas such as Complementarity determining region, Affinity maturation, Alanine, Receptor–ligand kinetics and Binding site as well as Mutant.
His main research concerns Antibody, Molecular biology, Cancer research, Antigen and Monoclonal antibody. His Antibody study is associated with Immunology. His work carried out in the field of Molecular biology brings together such families of science as In vivo, In vitro, Biodistribution, Biochemistry and Phage display.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Cancer, Epidermal growth factor receptor, Secretion and Pathology. His Antigen study incorporates themes from Radioimmunotherapy, Immunotoxin, Mutant and Recombinant DNA. His study on Monoclonal antibody also encompasses disciplines like
His primary areas of investigation include Antibody, Cancer research, Receptor, Biophysics and Ribosome-inactivating protein. The various areas that Gregory P. Adams examines in his Antibody study include Biochemistry, Flow cytometry and Antigen. His research integrates issues of Cancer cell, Immunogenic cell death, Cytotoxic T cell, Epithelial cell adhesion molecule and Bone morphogenetic protein in his study of Cancer research.
His Receptor research includes elements of Prostate, Chimera, Apoptosis, Fallopian tube and Lung. His work investigates the relationship between Biophysics and topics such as Molecular imaging that intersect with problems in Molecular biology, Receptor expression, Tumor antigen and Binding site. The study incorporates disciplines such as Cancer stem cell, Antibody-drug conjugate, Drug resistance and In vivo in addition to Trastuzumab.
Gregory P. Adams mostly deals with Cancer research, Antibody, Ovarian cancer, Cancer cell and Immunotherapy. His biological study spans a wide range of topics, including Mechanism of action and Efflux, Biochemistry, Small molecule, Protein biosynthesis. His Antibody research includes themes of Biophysics, Tumor penetration, Molecular biology, Fusion protein and Cytotoxic T cell.
His study focuses on the intersection of Ovarian cancer and fields such as Endometrial cancer with connections in the field of Receptor. His Receptor study integrates concerns from other disciplines, such as Molecular imaging, Tumor antigen and Binding site. The concepts of his Cancer cell study are interwoven with issues in Ovarian tumor, Human leukocyte antigen and Flow cytometry, Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Monoclonal antibody therapy of cancer
Gregory P Adams;Louis M Weiner.
Nature Biotechnology (2005)
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Gregory P. Adams;Robert Schier;Adrian M. McCall;Heidi H. Simmons.
Cancer Research (2001)
Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site
Robert Schier;Adrian McCall;Gregory P. Adams;Keith W. Marshall.
Journal of Molecular Biology (1996)
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
Robert Schier;Jacqueline Bye;Gerald Apell;Adrian McCall.
Journal of Molecular Biology (1996)
Affinity and avidity in antibody-based tumor targeting.
Stephen I. Rudnick;Gregory P. Adams.
Cancer Biotherapy and Radiopharmaceuticals (2009)
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.
Lily Yang;Hui Mao;Y. Andrew Wang;Zehong Cao.
Small (2008)
Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv
Gregory P. Adams;John E. McCartney;Mei-Sheng Tai;Hermann Oppermann.
Cancer Research (1993)
Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies
Gregory P. Adams;Robert Schier;Keith Marshall;Ellen J. Wolf.
Cancer Research (1998)
Monoclonal antibody therapy for cancer.
Margaret von Mehren;Gregory P. Adams;Louis M. Weiner.
Annual Review of Medicine (2003)
Expression of Mutated Epidermal Growth Factor Receptor by Non-Small Cell Lung Carcinomas
I. E. Garcia De Palazzo;G. P. Adams;Padma Sundareshan;A. J. Wong.
Cancer Research (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Georgetown University Medical Center
University of California, San Francisco
Harvard University
Fox Chase Cancer Center
Royal Institute of Technology
Drexel University
La Trobe University
Uppsala University
Harvard University
City Of Hope National Medical Center
Grenoble Alpes University
SRI International
Shanghai Jiao Tong University
Missouri University of Science and Technology
Waseda University
National University of Singapore
University of Paris-Sud
Chonnam National University
Agency for Science, Technology and Research
University Of Thessaly
Memorial Sloan Kettering Cancer Center
Harvard University
University of Miami
Vrije Universiteit Amsterdam
Durham University
Carnegie Mellon University